Targeting bromodomain protein ANCCA/ATAD2 enhances the efficacy of DNA‑damaging chemotherapy agents and radiation

Duan,Zhijian; Andrews,Nicolas   P.; Chen,Christopher   Z.; Fan,Ming; Wang,Junjian; Shen,Jing; Li,Jian‑Jian; Chen,Hong‑Wu

doi:10.3892/or.2019.7418

Targeting bromodomain protein ANCCA/ATAD2 enhances the efficacy of DNA‑damaging chemotherapy agents and radiation

Authors:
- Zhijian Duan
- Nicolas P. Andrews
- Christopher Z. Chen
- Ming Fan
- Junjian Wang
- Jing Shen
- Jian‑Jian Li
- Hong‑Wu Chen
View Affiliations

Affiliations: Department of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA 95817, USA, Department of Radiation Oncology, University of California, Davis, Sacramento, CA 95817, USA, Department of Pathology and Pathophysiology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, P.R. China
Published online on: November 27, 2019 https://doi.org/10.3892/or.2019.7418
Pages: 318-327

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bromodomain proteins such as BRD4 chromatin regulator are attractive cancer therapeutic targets. ANCCA (AAA+ nuclear coregulatory cancer‑associated protein, also known as ATPase family AAA domain containing 2 or ATAD2) is a novel oncology drug target and contains a bromodomain and an ATPase domain. Our research group as well as others previously identified ANCCA/ATAD2 as a putative oncogene and a poor prognosis factor in many types of cancer including triple‑negative breast cancer (TNBC). In the present study, it is reported for the first time that the expression of ANCCA was highly induced by DNA‑damaging chemotherapy agents such as carboplatin, doxorubicin and mitomycin C, as well as ionizing radiation. Notably, ANCCA is required for efficient dissolution of DNA damage foci and homologous recombination. Further studies revealed that ANCCA mediates the optimal expression and activation of DNA damage response and repair factors including Chk1, Chk2 and BRCA1, and that ANCCA is recruited to the promoter of BRCA1 in response to DNA damage. Moreover, ANCCA knockdown sensitizes TNBC cells to carboplatin. Collectively, these data provide the first evidence indicating that ANCCA is a novel mediator of DNA damage response and repair and that targeting ANCCA can enhance the efficacy of radiation and chemotherapies.

View Figures

View References

1	Liu B, Yip R and Zhou Z: Chromatin remodeling, DNA damage repair and aging. Curr Genomics. 13:533–547. 2012. View Article : Google Scholar : PubMed/NCBI
2	Soria G, Polo SE and Almouzni G: Prime, repair, restore: The active role of chromatin in the DNA damage response. Mol Cell. 46:722–734. 2012. View Article : Google Scholar : PubMed/NCBI
3	Price BD and D'Andrea AD: Chromatin remodeling at DNA double-strand breaks. Cell. 152:1344–1354. 2013. View Article : Google Scholar : PubMed/NCBI
4	Zou JX, Guo L, Revenko AS, Tepper CG, Gemo AT, Kung HJ and Chen HW: Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer. Cancer Res. 69:3339–3346. 2009. View Article : Google Scholar : PubMed/NCBI
5	Zou JX, Revenko AS, Li LB, Gemo AT and Chen HW: ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci USA. 104:18067–18072. 2007. View Article : Google Scholar : PubMed/NCBI
6	Kalashnikova EV, Revenko AS, Gemo AT, Andrews NP, Tepper CG, Zou JX, Cardiff RD, Borowsky AD and Chen HW: ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res. 70:9402–9412. 2010. View Article : Google Scholar : PubMed/NCBI
7	Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle V, Barbry P, Debernardi A, Brambilla C, Brambilla E, et al: Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene. 29:5171–5181. 2010. View Article : Google Scholar : PubMed/NCBI
8	Ciro M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F, Nucifero P, Pacchiana G, Capra M, Christensen J and Helin K: ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res. 69:8491–8498. 2009. View Article : Google Scholar : PubMed/NCBI
9	Zhang M, Zhang C, Du W, Yang X and Chen Z: ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker. Clin Transl Oncol. 18:776–781. 2016. View Article : Google Scholar : PubMed/NCBI
10	Yang J, Huang J, Luo L, Chen Z, Guo Y and Guo L: Significance of PRO2000/ANCCA expression, a novel proliferation-associated protein in hepatocellular carcinoma. Cancer Cell Int. 14:332014. View Article : Google Scholar : PubMed/NCBI
11	Krakstad C, Tangen IL, Hoivik EA, Halle MK, Berg A, Werner HM, Ræder MB, Kusonmano K, Zou JX, Øyan AM, et al: ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. Oncotarget. 6:28440–28452. 2015. View Article : Google Scholar : PubMed/NCBI
12	Hwang HW, Ha SY, Bang H and Park CK: ATAD2 as a poor prognostic marker for hepatocellular carcinoma after curative resection. Cancer Res Treat. 47:853–861. 2015. View Article : Google Scholar : PubMed/NCBI
13	Shang P, Meng F, Liu Y and Chen X: Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its correlation with tumor progression and poor prognosis. Tumour Biol. 36:4479–4485. 2015. View Article : Google Scholar : PubMed/NCBI
14	Zheng L, Li T, Zhang Y, Guo Y, Yao J, Dou L and Guo K: Oncogene ATAD2 promotes cell proliferation, invasion and migration in cervical cancer. Oncol Rep. 33:2337–2344. 2015. View Article : Google Scholar : PubMed/NCBI
15	Revenko AS, Kalashnikova EV, Gemo AT, Zou JX and Chen HW: Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark. Mol Cell Biol. 30:5260–5272. 2010. View Article : Google Scholar : PubMed/NCBI
16	Huang J, Yang J, Lei Y, Gao H, Wei T, Luo L, Zhang F, Chen H, Zeng Q and Guo L: An ANCCA/PRO2000-miR-520a-E2F2 regulatory loop as a driving force for the development of hepatocellular carcinoma. Oncogenesis. 5:e2292016. View Article : Google Scholar : PubMed/NCBI
17	Koo SJ, Fernández-Montalván AE, Badock V, Ott CJ, Holton SJ, von Ahsen O, Toedling J, Vittori S, Bradner JE and Gorjánácz M: ATAD2 is an epigenetic reader of newly synthesized histone marks during DNA replication. Oncotarget. 7:70323–70335. 2016. View Article : Google Scholar : PubMed/NCBI
18	Bamborough P, Chung CW, Furze RC, Grandi P, Michon AM, Watson RJ, Mitchell DJ, Barnett H, Prinjha RK, Rau C, et al: Aiming to miss a moving target: Bromo and extra terminal domain (BET) selectivity in constrained ATAD2 inhibitors. J Med Chem. 61:8321–8336. 2018. View Article : Google Scholar : PubMed/NCBI
19	Fernández-Montalván AE, Berger M, Kuropka B, Koo SJ, Badock V, Weiske J, Puetter V, Holton SJ, Stöckigt D, Ter Laak A, et al: Isoform-selective ATAD2 chemical probe with novel chemical structure and unusual mode of action. ACS Chem Biol. 12:2730–2736. 2017. View Article : Google Scholar : PubMed/NCBI
20	Lord CJ and Ashworth A: The DNA damage response and cancer therapy. Nature. 481:287–294. 2012. View Article : Google Scholar : PubMed/NCBI
21	Altieri F, Grillo C, Maceroni M and Chichiarelli S: DNA damage and repair: From molecular mechanisms to health implications. Antioxid Redox Signal. 10:891–937. 2008. View Article : Google Scholar : PubMed/NCBI
22	Fong YW, Cattoglio C and Tjian R: The intertwined roles of transcription and repair proteins. Mol Cell. 52:291–302. 2013. View Article : Google Scholar : PubMed/NCBI
23	Biswas AK and Johnson DG: Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage. Cancer Res. 72:13–17. 2012. View Article : Google Scholar : PubMed/NCBI
24	Hauer MH and Gasser SM: Chromatin and nucleosome dynamics in DNA damage and repair. Genes Dev. 31:2204–2221. 2017. View Article : Google Scholar : PubMed/NCBI
25	Pei H, Zhang L, Luo K, Qin Y, Chesi M, Fei F, Bergsagel PL, Wang L, You Z and Lou Z: MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature. 470:124–128. 2011. View Article : Google Scholar : PubMed/NCBI
26	Li X, Baek G, Ramanand SG, Sharp A, Gao Y, Yuan W, Welti J, Rodrigues DN, Dolling D, Figueiredo I, et al: BRD4 promotes DNA repair and mediates the formation of TMPRSS2-ERG gene rearrangements in prostate cancer. Cell Rep. 22:796–808. 2018. View Article : Google Scholar : PubMed/NCBI
27	Floyd SR, Pacold ME, Huang Q, Clarke SM, Lam FC, Cannell IG, Bryson BD, Rameseder J, Lee MJ, Blake EJ, et al: The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature. 498:246–250. 2013. View Article : Google Scholar : PubMed/NCBI
28	Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, et al: ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med. 22:488–496. 2016. View Article : Google Scholar : PubMed/NCBI
29	Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, Belmaaza A, Wouters B and Bristow RG: Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res. 68:605–614. 2008. View Article : Google Scholar : PubMed/NCBI
30	Luoto KR, Meng AX, Wasylishen AR, Zhao H, Coackley CL, Penn LZ and Bristow RG: Tumor cell kill by c-MYC depletion: Role of MYC-regulated genes that control DNA double-strand break repair. Cancer Res. 70:8748–8759. 2010. View Article : Google Scholar : PubMed/NCBI
31	Boeing S, Williamson L, Encheva V, Gori I, Saunders RE, Instrell R, Aygün O, Rodriguez-Martinez M, Weems JC, Kelly GP, et al: Multiomic analysis of the UV-induced DNA damage response. Cell Rep. 15:1597–1610. 2016. View Article : Google Scholar : PubMed/NCBI
32	Christmann M and Kaina B: Transcriptional regulation of human DNA repair genes following genotoxic stress: Trigger mechanisms, inducible responses and genotoxic adaptation. Nucleic Acids Res. 41:8403–8420. 2013. View Article : Google Scholar : PubMed/NCBI
33	De Siervi A, De Luca P, Byun JS, Di LJ, Fufa T, Haggerty CM, Vazquez E, Moiola C, Longo DL and Gardner K: Transcriptional autoregulation by BRCA1. Cancer Res. 70:532–542. 2010. View Article : Google Scholar : PubMed/NCBI
34	Wang J, Zuo J, Wang M, Ma X, Gao K, Bai X, Wang N, Xie W and Liu H: Pololike kinase 4 promotes tumorigenesis and induces resistance to radiotherapy in glioblastoma. Oncol Rep. 41:2159–2167. 2019.PubMed/NCBI
35	Morozumi Y, Boussouar F, Tan M, Chaikuad A, Jamshidikia M, Colak G, He H, Nie L, Petosa C, de Dieuleveult M, et al: Atad2 is a generalist facilitator of chromatin dynamics in embryonic stem cells. J Mol Cell Biol. 8:349–362. 2016. View Article : Google Scholar : PubMed/NCBI
36	Zou JX, Duan Z, Wang J, Sokolov A, Xu J, Chen CZ, Li JJ and Chen HW: Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance. Mol Cancer Res. 12:539–549. 2014. View Article : Google Scholar : PubMed/NCBI